Applied Genetic Technologies Corporation (AGTC)
Chart Events
Performance Outlook
| Previous Close | 0.4235 |
| Open | 0.4292 |
| Bid | 0.3899 x 800 |
| Ask | 0.3900 x 800 |
| Day's Range | 0.3849 - 0.4317 |
| 52 Week Range | 0.3470 - 3.6900 |
| Volume | |
| Avg. Volume | 1,224,338 |
| Market Cap | 25.721M |
| Beta (5Y Monthly) | 1.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4600 |
| Earnings Date | Sep 21, 2022 - Sep 26, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AGTC
Related Research
- Applied Genetic Technologies CoAnalyst Report: Biogen Inc.Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.RatingFair ValueEconomic Moat18 days agoMorningstar
- GlobeNewswire
AGTC to Participate in Upcoming Investor Conferences
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor confere
- GlobeNewswire
AGTC Receives Positive Type C Meeting Feedback from the FDA for the Company’s Design and Operating Procedures of its Planned cGMP Manufacturing Facility
— FDA feedback marks a key milestone in the construction of the facility expected to support AGTC’s pipeline, including the late-stage development and potential commercialization of AGTC’s X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs — GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of a
- InvestorPlace
6 Penny Stocks With 1,000% Upside Potential
Investors in penny stocks know that they are an inherently risky proposition. That goes double for any investor just getting into this market. But with great risk comes great reward. In this case, I think these are penny stocks with 1,000% upside potential. That would be a return any investor would love. First, the methodology for assessing upside potential: This is simply a measure of the current price against the target price. So, all of these stocks above could turn $1,000 into $11,000 is ana
